RIO DE JANEIRO, BRAZIL - Phase 1 clinical trials conducted in Thailand have shown that the Butanvac, a new Covid-19 vaccine candidate developed by the São Paulo state-owned Butantan Institute, is safe and has a powerful immunogenicity. The results were described in an article published last September 22 in the MedRxiv preprints website.
The trial had the participation of researchers from Mahidol University in Bangkok (Thailand), Icahn Mount Sinai School of Medicine New York (USA), and the University of Texas in Austin (USA). Internationally named NDV-HXP-S, the Butanvac is also being tested in Vietnam, in addition . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here
